MedTrace Logo

Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

NCT01213329 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to check the T and B cells of the immune system in 50 newly transplanted patients whom have received a kidney (50 recipients and 50 donors totaling 100 anticipated participants). This will be done to see how the Standard of Care (SOC) anti-rejection medication, Alemtuzumab (Campath 1-H®) affects these cells- Campath 1-H® reduces the number of T cells produced by one's body.

Conditions

  • Kidney Transplant

Interventions

DRUG

Alemtuzumab

All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.

Sponsors & Collaborators

Principal Investigators

  • Lorenzo Gallon, MD · Northwestern University, Northwestern Memorial Hospital, Northwestern Medical Faculty Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213329 on ClinicalTrials.gov